PHARMACOGENOMICS: PERSONALIZED MEDICINE BASED ON GENETIC FACTORS.

Main Article Content

Waleed Ahmad Saeed Alamri
Khalid Abdullah Algarni
Mohammed Abdullah Hamed Alqurashi
Mohammed Sanad Butihan Althobaiti
Ahmed Abdulaziz Alghamdi
Ahmed Saleh Alharthi

Keywords

pharmacogenomics, personalized medicine, genetic factors, drug response, genomics, clinical practice

Abstract

Pharmacogenomics is a rapidly evolving field that focuses on how an individual's genetic makeup can affect their response to certain drugs. This personalized approach to medicine takes into consideration genetic factors that can influence drug metabolism, efficacy, and potential adverse reactions. By integrating genomics into clinical practice, healthcare providers can tailor treatment plans to optimize outcomes for patients. This essay explores the concept of pharmacogenomics and its implications for personalized medicine, highlighting the methods, results, and discussions surrounding this revolutionary approach.

Abstract 37 | PDF Downloads 39

References

1. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467-475.
2. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350.
3. Swen JJ, Nijenhuis M, KuoHansen R, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
4. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496-526.
5. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther. 2013;94(2):214-217.
6. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci. 2012;33(6):314-323.
7. Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine induced hypersensitivity reactions. Epilepsia. 2014;55(4):496-506.
8. Ratain MJ, Nakamura Y, Cox NJ, et al. Clinical pharmacogenetics implementation consortium guidelines for clopidogrel genotype and clopidogrel and CYP2C19 testing. Clin Pharmacol Ther. 2011;90(2):328-332.
9. Lee SC, Chong L, Teo YY. Effect of CYP2C19 polymorphism on adverse clinical events in clopidogrel-treated patients is influenced by the patients' weight. Pharmacogenomics. 2009;10(4):559-566.
10. Kadam RA, Borde SU, Madas SA, Salagre SB, Limaye RP. Challenges in recruitment and retention of clinical trial subjects. Perspect Clin Res. 2016;7(3):137-143.

Most read articles by the same author(s)